Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Acorda Therapeutics

DB:CDG
Snowflake Description

Overvalued with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CDG
DB
$45M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The last earnings update was 40 days ago. More info.


Add to Portfolio Compare Print
  • Acorda Therapeutics has significant price volatility in the past 3 months.
CDG Share Price and Events
7 Day Returns
2.5%
DB:CDG
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-92.5%
DB:CDG
-7.4%
DE Biotechs
-14.2%
DE Market
CDG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Acorda Therapeutics (CDG) 2.5% -12.2% -58.9% -92.5% -94.7% -97.4%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • CDG underperformed the Biotechs industry which returned -7.4% over the past year.
  • CDG underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
CDG
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Acorda Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Acorda Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €0.83.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Acorda Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Acorda Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CDG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-5.75
NasdaqGS:ACOR Share Price ** NasdaqGS (2020-04-08) in USD $0.98
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Acorda Therapeutics.

DB:CDG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGS:ACOR Share Price ÷ EPS (both in USD)

= 0.98 ÷ -5.75

-0.17x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Acorda Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Acorda Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Acorda Therapeutics's expected growth come at a high price?
Raw Data
DB:CDG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.17x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
50.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Acorda Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Acorda Therapeutics's assets?
Raw Data
DB:CDG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $6.52
NasdaqGS:ACOR Share Price * NasdaqGS (2020-04-08) in USD $0.98
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:CDG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGS:ACOR Share Price ÷ Book Value per Share (both in USD)

= 0.98 ÷ 6.52

0.15x

* Primary Listing of Acorda Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Acorda Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Acorda Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Acorda Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Acorda Therapeutics expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
50.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Acorda Therapeutics expected to grow at an attractive rate?
  • Unable to compare Acorda Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Acorda Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Acorda Therapeutics's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CDG Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CDG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 50.5%
DB:CDG Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 3.4%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CDG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CDG Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 209 -32 2
2023-12-31 201 67 -34 3
2022-12-31 173 47 -57 4
2021-12-31 137 -31 -89 7
2020-12-31 144 -22 -91 6
2020-04-08
DB:CDG Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 192 -128 -273
2019-09-30 211 -129 -329
2019-06-30 306 -27 -79
2019-03-31 409 45 -6
2018-12-31 471 151 34
2018-09-30 591 224 -147
2018-06-30 589 197 -158
2018-03-31 575 151 -213
2017-12-31 588 97 -223
2017-09-30 541 69 -55
2017-06-30 535 23 -43
2017-03-31 523 3 -53

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Acorda Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Acorda Therapeutics's revenue is expected to grow by 3.4% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CDG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from Acorda Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CDG Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.50 0.00 -0.99 2.00
2023-12-31 -0.51 0.79 -1.41 3.00
2022-12-31 -0.82 0.39 -2.06 4.00
2021-12-31 -1.55 -0.20 -3.18 7.00
2020-12-31 -1.81 -0.91 -2.79 6.00
2020-04-08
DB:CDG Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -5.75
2019-09-30 -6.93
2019-06-30 -1.67
2019-03-31 -0.12
2018-12-31 0.72
2018-09-30 -3.15
2018-06-30 -3.42
2018-03-31 -4.60
2017-12-31 -4.86
2017-09-30 -1.21
2017-06-30 -0.94
2017-03-31 -1.16

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Acorda Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Acorda Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Acorda Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Acorda Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Acorda Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Acorda Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare Acorda Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Acorda Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Acorda Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Acorda Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CDG Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 192.41 -272.97 189.85 58.68
2019-09-30 211.06 -329.03 188.34 76.92
2019-06-30 306.16 -79.41 183.21 83.70
2019-03-31 409.41 -5.72 177.28 90.65
2018-12-31 471.43 33.68 172.15 105.18
2018-09-30 590.68 -146.98 172.25 108.97
2018-06-30 588.93 -158.26 169.42 119.40
2018-03-31 575.07 -212.65 174.50 144.67
2017-12-31 588.29 -223.36 179.52 160.61
2017-09-30 540.52 -55.39 183.55 184.76
2017-06-30 535.06 -42.92 197.61 206.25
2017-03-31 523.08 -53.00 210.88 205.36
2016-12-31 519.60 -34.62 217.84 203.44
2016-09-30 509.88 -22.32 229.37 193.63
2016-06-30 522.46 -5.65 225.63 182.21
2016-03-31 508.71 13.62 215.84 163.14
2015-12-31 492.66 11.06 205.23 149.21
2015-09-30 479.63 2.18 201.90 131.14
2015-06-30 437.39 10.19 198.67 104.37
2015-03-31 420.81 13.88 196.49 89.58
2014-12-31 401.48 17.67 201.81 73.47
2014-09-30 376.20 23.53 191.36 61.85
2014-06-30 355.16 19.06 185.88 59.11
2014-03-31 345.08 18.28 183.24 55.88
2013-12-31 336.43 16.44 184.55 53.88
2013-09-30 325.31 143.22 183.47 57.77
2013-06-30 317.83 145.34 181.25 55.96

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Acorda Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Acorda Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Acorda Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Acorda Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Acorda Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Acorda Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Acorda Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Acorda Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Acorda Therapeutics's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of Acorda Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Acorda Therapeutics Company Filings, last reported 3 months ago.

DB:CDG Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 310.82 218.87 125.84
2019-09-30 281.34 351.49 253.16
2019-06-30 544.84 349.63 296.89
2019-03-31 566.59 346.46 343.25
2018-12-31 611.98 343.76 445.55
2018-09-30 598.63 341.46 460.95
2018-06-30 606.64 339.01 391.72
2018-03-31 549.93 337.79 333.04
2017-12-31 519.99 335.12 307.07
2017-09-30 679.99 332.22 192.50
2017-06-30 689.72 328.71 141.14
2017-03-31 676.13 327.12 133.62
2016-12-31 664.21 331.05 158.54
2016-09-30 666.77 298.25 127.94
2016-06-30 681.54 295.98 137.40
2016-03-31 684.01 293.74 431.41
2015-12-31 603.03 292.70 353.31
2015-09-30 574.89 295.73 323.43
2015-06-30 560.28 293.76 301.72
2015-03-31 549.02 291.81 299.70
2014-12-31 540.26 291.03 307.62
2014-09-30 522.91 289.13 766.44
2014-06-30 500.38 287.23 605.85
2014-03-31 450.52 3.26 270.42
2013-12-31 440.35 4.37 273.93
2013-09-30 426.39 4.34 292.31
2013-06-30 404.80 4.31 303.33
  • Acorda Therapeutics's level of debt (70.4%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (53.9% vs 70.4% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Acorda Therapeutics has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if Acorda Therapeutics has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess Acorda Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Acorda Therapeutics has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Acorda Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Acorda Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Acorda Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Acorda Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Acorda Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CDG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CDG Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31 0.00 1.00
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Acorda Therapeutics has not reported any payouts.
  • Unable to verify if Acorda Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Acorda Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Acorda Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Acorda Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Acorda Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Acorda Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Acorda Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Acorda Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ron Cohen
COMPENSATION $2,414,371
AGE 63
TENURE AS CEO 25.3 years
CEO Bio

Dr. Ron Cohen, M.D., has been the Founder of Acorda Therapeutics, Inc. since 1995 and has been its Chief Executive Officer and President since 1995. Dr. Cohen served as Principal in the startup of Advanced Tissue Sciences, Inc. He served as the Chairman Emeritus of the New York Biotechnology Association and served as its Chairman and Director. Dr. Cohen serves as the Chairman of Emerging Company Section at the (Biotechnology Innovation Organization) also known as Biotechnology Industry Organization (BIO). Dr. Cohen served as the Chairman of Acorda Therapeutics, Inc. and has been its Director since 1995. Dr. Cohen serves as a Director of Zymenex A/S, a Danish pharmaceutical company. He served as a Director of Dyax Corp. from November 2011 to January 22, 2016. He also serves on the Scientific Advisory Board of the Daniel Heumann Fund and as a member of the Columbia-Presbyterian Health Sciences Advisory Council. He serves on the Advisory Editorial Board of BioPeople magazine. He has been a Non-Executive Director at Vascular Biogenics Ltd. since February 11, 2015. Dr. Cohen serves on the board of directors of VBL Therapeutics. He has been a Director of Biotie Therapies Corp. since May 11, 2016. He served as a Director at Ceregene, Inc. He received his B.A. degree with honors in Psychology from Princeton University and his M.D from the Columbia College of Physicians & Surgeons. He was awarded Columbia University’s Alumni Medal for Distinguished Service. In 2010, Dr. Cohen was named NeuroInvestment’s (now called NeuroPerspective) CEO of the Year and in 2009 he was recognized by PharmaVoice Magazine as one of the 100 Most Inspirational People in the Biopharmaceutical Industry. Dr. Cohen is a recipient of the Ernst & Young Entrepreneur of the Year Award for the New York Metropolitan Region, and an inductee into the National Spinal Cord Injury Association’s “Spinal Cord Injury Hall of Fame.” In 2010, Dr. Cohen was recognized by NewYork BIO as its "The Cure Starts Here" Business Leader of the Year. Dr. Cohen completed a residency in Internal Medicine at the University of Virginia Medical Center and is Board Certified in Internal Medicine.

CEO Compensation
  • Ron's compensation has increased whilst company is loss making.
  • Ron's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Acorda Therapeutics management team in years:

5.3
Average Tenure
63
Average Age
  • The average tenure for the Acorda Therapeutics management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Ron Cohen

TITLE
Founder
COMPENSATION
$2M
AGE
63
TENURE
25.3 yrs

Dave Lawrence

TITLE
CTO, Chief of Business Operations & Principal Accounting Officer
COMPENSATION
$973K
AGE
61
TENURE
6.5 yrs

Burkhard Blank

TITLE
Chief Medical Officer and Head of R&D
COMPENSATION
$1M
AGE
64
TENURE
4.3 yrs

Jane Wasman

TITLE
Consultant
COMPENSATION
$1M
AGE
63
TENURE
0.3 yrs

Felicia Vonella

TITLE
Vice President of Investor Relations

Andrew Mayer

TITLE
Senior VP
TENURE
0.4 yrs

Tierney Saccavino

TITLE
Executive Vice President of Corporate Communications
TENURE
5.3 yrs

Denise Duca

TITLE
Executive Vice President of Human Resources
TENURE
5.3 yrs

Andrew Blight

TITLE
Chief Scientific Officer Emeritus
COMPENSATION
$1M
AGE
68
TENURE
20.3 yrs

Lauren Sabella

TITLE
Chief Commercial Officer
COMPENSATION
$1M
AGE
58
TENURE
10.3 yrs
Board of Directors Tenure

Average tenure and age of the Acorda Therapeutics board of directors in years:

15.1
Average Tenure
65
Average Age
  • The average tenure for the Acorda Therapeutics board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

John Kelley

TITLE
Non-executive Chairman
COMPENSATION
$297K
AGE
65
TENURE
0.4 yrs

Ron Cohen

TITLE
Founder
COMPENSATION
$2M
AGE
63
TENURE
25.3 yrs

Sandra Panem

TITLE
Independent Director
COMPENSATION
$294K
AGE
72
TENURE
22.3 yrs

Steve Rauscher

TITLE
Independent Director
COMPENSATION
$292K
AGE
65
TENURE
15.1 yrs

Jeff Randall

TITLE
Independent Director
COMPENSATION
$290K
AGE
75
TENURE
14.3 yrs

Melitta Schachner

TITLE
Member of Scientific Advisory Board

Patrick Tresco

TITLE
Member of Scientific Advisory Board

Stephen Waxman

TITLE
Member of Scientific Advisory Board

Mary Bunge

TITLE
Member of Scientific Advisory Board

Mark Tuszynski

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Acorda Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Acorda Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson’s disease; ARCUS product for the treatment of acute migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson’s disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Details
Name: Acorda Therapeutics, Inc.
CDG
Exchange: DB
Founded: 1995
$40,937,408
47,991,834
Website: http://www.acorda.com
Address: Acorda Therapeutics, Inc.
420 Saw Mill River Road,
Ardsley,
New York, 10502,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGS ACOR Common Stock Nasdaq Global Select US USD 10. Feb 2006
DB CDG Common Stock Deutsche Boerse AG DE EUR 10. Feb 2006
BRSE CDG Common Stock Berne Stock Exchange CH CHF 10. Feb 2006
Number of employees
Current staff
Staff numbers
344
Acorda Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 21:06
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2020/02/28
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.